| Literature DB >> 33446323 |
Sujit S Nair1, Rachel Weil2, Zachary Dovey2, Avery Davis2, Ashutosh K Tewari3.
Abstract
Bladder cancer has been successfully treated with immunotherapy, whereas prostate cancer is a cold tumor with inadequate immune-related treatment response. A greater understanding of the tumor microenvironment and methods for harnessing the immune system to address tumor growth will be needed to improve immunotherapies for both prostate and bladder cancer. Here, we provide an overview of prostate and bladder cancer, including fundamental aspects of the disease and treatment, the elaborate cellular makeup of the tumor microenvironment, and methods for exploiting relevant pathways to develop more effective treatments.Entities:
Keywords: Bladder cancer; Immunoediting; Immunotherapy; Neoadjuvant treatment; Prostate cancer; Tumor microenvironment; Vaccines
Year: 2020 PMID: 33446323 DOI: 10.1016/j.ucl.2020.10.005
Source DB: PubMed Journal: Urol Clin North Am ISSN: 0094-0143 Impact factor: 2.241